Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Merck
Fuji
Deloitte
Mallinckrodt
Dow
Express Scripts
Farmers Insurance
Fish and Richardson
Queensland Health

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,213,804

« Back to Dashboard

Summary for Patent: 5,213,804

Title: Solid tumor treatment method and composition
Abstract:A liposome composition for localizing an anti-tumor compound to a solid tumor via the bloodstream. The liposomes, which contain the agent in entrapped form, are composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer, and have sizes in a selected size range between 0.07 and 0.12 microns. After intravenous administration, the liposomes are taken up by the tumor within 24-48 hours, for site-specific release of entrapped compound into the tumor. In one composition for use in treating a solid tumor, the compound is an anthracycline antibiotic drug which is entrapped in the liposomes at a concentration of greater than about 50 .mu.g agent/.mu.mole liposome lipid. The method results in regression of solid colon and breast carcinomas which are refractory to anthracycline antibiotic drugs administered in free form or entrapped in conventional liposomes.
Inventor(s): Martin; Francis J. (San Francisco, CA), Woodle; Martin C. (Menlo Park, CA), Redemann; Carl (Walnut Creek, CA), Yau-Young; Annie (Palo Alto, CA)
Assignee: Liposome Technology, Inc. (Menlo Park, CA)
Application Number:07/642,321
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Compound; Use;

No matches for this query

International Patent Family for Patent: 5,213,804

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria115401► Subscribe
Austria122229► Subscribe
Austria142483► Subscribe
Austria152614► Subscribe
Australia5323194► Subscribe
Australia642679► Subscribe
Australia6527294► Subscribe
Australia654120► Subscribe
Australia6637490► Subscribe
Australia6898291► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
QuintilesIMS
Mallinckrodt
Express Scripts
Daiichi Sankyo
Dow
Harvard Business School
Healthtrust
Boehringer Ingelheim
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot